# A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

> **NCT03588130** · PHASE2 · COMPLETED · sponsor: **MediWound Ltd** · enrollment: 120 (actual)

## Conditions studied

- Venous Leg Ulcer

## Interventions

- **DRUG:** EscharEx (5% EX-02 formulation)
- **DRUG:** Gel Vehicle
- **DRUG:** Non-surgical standard of care (NSSOC)

## Key facts

- **NCT ID:** NCT03588130
- **Lead sponsor:** MediWound Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-02
- **Primary completion:** 2021-12-07
- **Final completion:** 2022-03-23
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588130, "A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03588130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*